
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is expected to see strong growth in the near-term due to the continued momentum of its products Giapreza and Xacduro, with solid potential for acceleration and further revenue growth in the future from upcoming guideline endorsements and new product launches. The company's reliance on royalty revenue and its successful track record in asset purchases and investments also suggest a strong foundation for future growth. Despite a recent top-line miss, Innoviva's bottom-line performance exceeded expectations due to gains from its investment portfolio, and the company's strong cash position further supports its potential for future success. Based on these factors, the outlook for Innoviva's stock appears promising for investors.
Bears say
Innoviva is facing significant challenges in generating substantial revenue, with a small increase in license and other revenue not enough to offset declines in key products like Anoro and Trelegy, while also facing negative impacts from its investment in Armata Pharmaceuticals. Additionally, while the acquisition of Lyndra Therapeutics and its proprietary LYNX drug delivery platform has potential, the company's overall financial outlook remains weak. Therefore, the future growth and success of Innoviva are uncertain, leading to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares